Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Earnings Data
Report Date
Jan 30, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
10.56Last Year’s EPS
12.07Same Quarter Last Year
Moderate Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Regeneron demonstrated strong sales growth in key products like Dupixent and Libtayo, along with significant R&D pipeline progress. However, challenges such as affordability issues for EYLEA and FDA-related setbacks tempered some positive outcomes. Overall, the company shows a robust financial position and commitment to innovation, but faces operational hurdles that need addressing.Company Guidance
Dupixent Sales Growth
Worldwide net product sales for Dupixent increased by 26% compared to the third quarter of last year. In the U.S., Dupixent net product sales grew 28%.
Libtayo Sales and FDA Approval
Global Libtayo net product sales were $365 million, up 24% on a constant currency basis. The FDA approved Libtayo for high-risk adjuvant cutaneous squamous cell carcinoma.
EYLEA HD Performance
EYLEA HD in the U.S. grew by 10%, with net product sales reaching $431 million, an all-time high.
R&D Pipeline Progress
Positive Phase III or registration-enabling data for six distinct programs in immunology, neurology, allergy, and rare diseases.
Regeneron's Financial Strength
Generated $3.2 billion in free cash flow through the first 9 months of 2025, with cash and marketable securities less debt of approximately $16 billion.
REGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
REGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 28, 2025 | $585.31 | $654.48 | +11.82% |
Aug 07, 2025 | $554.29 | $558.95 | +0.84% |
Apr 29, 2025 | $609.03 | $567.21 | -6.87% |
Feb 04, 2025 | $664.00 | $694.07 | +4.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Regeneron (REGN) report earnings?
Regeneron (REGN) is schdueled to report earning on Jan 30, 2026, Before Open (Confirmed).
What is Regeneron (REGN) earnings time?
Regeneron (REGN) earnings time is at Jan 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is REGN EPS forecast?
REGN EPS forecast for the fiscal quarter 2025 (Q4) is 10.56.
